mProX™ Human FAP Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human FAP Stable Cell Line (S01YF-1023-PY268). Click the button above to contact us or submit your feedback about this product.
Alex Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Alex Johnson (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Significant reduction in cell viability, as evidenced by the growth curves determined through MTT assay, was observed when FAP suppression was implemented, in contrast to sh-con cells.
A decrease in the expression of FAP was observed in shRNA-FAP-1 and -2 cells when compared with shRNA-con cells through western blotting, with β-Actin serving as the loading control. MTT cell viability assays were conducted on days 1-6 of KB cells expressing the shRNA-FAP-1 and 2 or shRNA-con vectors, demonstrating stable knockdown effects.
Ref: Wang, H., et al. "Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma." Cell death & disease 5.4 (2014): e1155-e1155.
Pubmed: 24722280
DOI: 10.1038/cddis.2014.122
Research Highlights
Yu, Wei. et al. "Development and validation of risk prediction and neural network models for dilated cardiomyopathy based on WGCNA." Frontiers in medicine, 2023.
Dilated cardiomyopathy (DCM) is a cardiac disorder that presents with ventricular dilatation and decreased myocardial contractility, leading to a significant mortality risk. Despite ongoing research, the molecular mechanisms underlying DCM remain unidentified. Hence, there is a critical need to identify potential biomarkers and therapeutic interventions for this condition.
Yu, Wei. et al. "Development and validation of risk prediction and neural network models for dilated cardiomyopathy based on WGCNA." Frontiers in medicine, 2023.
Pubmed:
37869159
DOI:
10.3389/fmed.2023.1239056
Wang, Hong. et al. "Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC)." International immunopharmacology, 2023.
Recent studies have shown that oxymatrine (Om) and astragaloside IV (As), two Chinese Medicine effective constituents, have potential in treating triple-negative breast cancer (TNBC) by targeting the disease's aggressive nature and immunosuppressive microenvironment. However, the effects of these compounds on TNBC and their mechanisms are not fully understood. This study aims to investigate the impact of Om and As on the immunosuppressive microenvironment of TNBC and uncover their potential mechanism. Using trans-cancer-associated fibroblasts (CAFs) infiltration and co-culture systems, the study found that Om effectively suppressed CAFs' activation and promoted T cell infiltration, while As improved the mitochondrial activity of T cells. Furthermore, in an in situ TNBC mouse model, the optimal ratio of Om and As (2:1) was found to enhance tumor suppression and improve the infiltration of CD4 and CD8 T cells at the tumor site.
Wang, Hong. et al. "Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC)." International immunopharmacology, 2023.
Pubmed:
37866315
DOI:
10.1016/j.intimp.2023.111026
